Skip to main content
. Author manuscript; available in PMC: 2022 Oct 7.
Published in final edited form as: Clin Cancer Res. 2022 Jun 13;28(12):2704–2714. doi: 10.1158/1078-0432.CCR-21-3581

Figure 7:

Figure 7:

Genomic profiling of advanced pancreatic adenocarcinoma to determine targetable molecular abnormalities. Drugs with an * indicate FDA-approved agents for treatment in pancreatic adenocarcinoma. KRAS WT tumors are enriched with several targetable mutations when compared to KRAS MT tumors. Currently, olaparib approval by the FDA is limited to treating patients with germline BRCA1/2 mutations only. WT: wild type. MT: mutant. PDAC: pancreatic ductal adenocarcinoma. SOC: standard of care.